جست‌وجوی استاد و پژوهشگر

Deni S. Galileoمشاهده پروفایل

استاد

• Cell Migration
• Neurobiology
• Developmental Biology
• +۳ مورد دیگر

Deni S. Galileo is a Professor in the Department of Biological Sciences at the University of Delaware. His research focuses on cell migration mechanisms in the developing brain and malignant gliomas, utilizing chick embryo models and retroviral gene transfer technologies. His work explores how integrins, extracellular matrix molecules, and adhesion proteins like L1CAM regulate normal and abnormal cell migration. Key projects include developing novel models for studying glioma invasiveness and breast cancer brain metastases, and investigating the role of QSOX1 and PMCA4 in tumor progression. Education: B.A., New College of Florida Ph.D., University of Florida College of Medicine and Whitney Laboratory Postdoctoral Research, Washington University School of Medicine (St. Louis) Research interests span developmental neurobiology, tumor biology, and gene therapy. Current projects include: Control of glioma invasiveness via L1CAM Integrins' roles in neuronal migration and survival Ex vivo analysis of glioblastoma behavior using chick embryos His lab has pioneered the use of replication-competent retroviral vectors and in ovo electroporation for widespread protein misexpression in developing brains. Collaborations with Dr. John Koh (Chemistry and Biochemistry) explore axon outgrowth on gene-patterned cell monolayers. Lab Resources: Office 232 Wolf Hall, Lab 248 Wolf Hall Teaching: Courses include Cell Biology (BISC 305), Developmental Neurobiology (BISC 439/639), and Special Topics in Modern Biological Microscopy (BISC 400). Notable contributions include establishing chick embryo models for studying glioma and breast cancer metastasis to the brain, and discovering roles for integrin α6β1 and α8β1 in cell migration and survival.

Neville Sanjanaمشاهده پروفایل

دانشیار

• Genome Engineering
• Neuroscience
• Cancer Research
• +۴ مورد دیگر

Neville Sanjana is an Associate Professor at the Department of Neuroscience , NYU Grossman School of Medicine , with a joint affiliation at the New York Genome Center . His academic journey began with a PhD at Massachusetts Institute of Technology . Research Interests in genome engineering, CRISPR technology, and functional genomics focus on: Dissecting noncoding genomic elements across cancers Developing high-throughput CRISPR screening methods Engineering therapies for neurological and genetic diseases Understanding transcriptional regulation in neuronal differentiation Recent Articles span cancer genomics, synthetic biology, and CRISPR-based diagnostics, with a thematic emphasis on: Drug resistance mechanisms in melanoma Noncoding element function in disease Advancements in base and prime editing Applications in immunotherapy and hemoglobin disorders Scientific Honors : NIH Director's New Innovator Award Sidney Kimmel Scholars Program DARPA Young Faculty Award Simons Foundation Autism Research Initiative Melanoma Research Alliance Young Investigator Award Teaching : In Spring 2022, he taught Special Topics: Genome Engineering (BIOL-UA 920) at NYU Biology, covering CRISPR evolution, gene therapies, and ethical implications of genome editing. Lab Operations : The Sanjana Lab operates from two locations - NY Genome Center (101 Avenue of the Americas, 4th floor, New York, NY 10013) and NYU Biology (755 Brown, 100 Washington Sq East, New York, NY 10003).

Janine Reichenbachمشاهده پروفایل

استاد

• Somatic Gene Therapy
• Primary Immunodeficiencies
• Hematopoietic Stem Cell Research
• +۴ مورد دیگر

Prof. Dr. med. Janine Reichenbach is a full professor and head of the Somatic Gene Therapy department at the University of Zurich, affiliated with the University Children's Hospital Zurich. She holds dual board certifications in Pediatrics and Adolescent Medicine (Germany/Switzerland) and Allergology & Clinical Immunology (Switzerland). Her career spans over two decades of translational research bridging basic science and clinical implementation of gene therapies. Education: MD from Goethe University Frankfurt (1995-1997), medical training in Germany (1997-2000), and specialist certifications in Switzerland (2005-2009). Research Focus: Translational development of hematopoietic stem cell-based gene therapies for primary immunodeficiencies, particularly chronic granulomatous disease (CGD) and ataxia telangiectasia (A-T). Key projects include lentiviral vector design, genome editing at ATM locus, and myeloid-targeted therapies with brain-crossing potential. Awards: Recipient of the 2010 Walther und Gertrud Siegenthaler Stiftung prize. Grants: Leads Swiss National Science Foundation projects, University Research Priority Programs (URPP Itinerare), Clinical Research Priority Programs (CRPP ImmuGene), and Wyss Centre collaborations. Leadership: Principal investigator in EU-FP7 projects CELL-PID and NET4CGD, steering committee member for SCID newborn screening, and co-founder of international research networks.

Kah Whye Pengمشاهده پروفایل

استاد

• Oncolytic Virotherapy
• Cancer Immunotherapy
• Viral Therapeutics
• +۱۲ مورد دیگر

Kah Whye Peng, Ph.D., is a Professor of Oncology at Mayo Clinic in Rochester, Minnesota, where he holds a primary appointment as a Consultant in the Department of Molecular Medicine and a joint appointment in the Department of Obstetrics & Gynecology. His research is centered on developing replication-competent viruses as novel therapeutics for cancer, particularly ovarian cancer and multiple myeloma. Ph.D. in Gene Therapy, Cambridge Centre for Protein Engineering, Cambridge University M.Sc. in Biochemistry, National University of Singapore B.Sc. in Zoology, National University of Singapore Dr. Peng’s research focuses on oncolytic virotherapy, utilizing the measles virus (Edmonston strain) and vesicular stomatitis virus (Indiana strain) for tumor-selective therapy. His lab specializes in enhancing virus delivery through tumor retargeting and mesenchymal stem cell (MSC) carriers, overcoming antiviral immune responses, and developing noninvasive imaging techniques to monitor viral activity. His work has led to clinical trials testing recombinant measles viruses (MV-CEA, MV-NIS) and MSC-mediated delivery systems. His recent publications highlight advancements in oncolytic virotherapy, including the development of engineered viruses for enhanced antitumor immunity, combination strategies with immunotherapeutics, and innovative vaccine platforms using measles vectors for SARS-CoV-2. His research spans molecular engineering, preclinical testing, and clinical translation, demonstrating a strong trajectory in cancer biotherapeutics. Oncolytic virotherapy Cancer immunotherapy Gene therapy Translational research Molecular medicine Dr. Peng has been a co-investigator on multiple NIH-funded grants, including a phase I trial of vesicular stomatitis virus for metastatic endometrial cancer and a long-term project on uterine serous carcinoma. He has also led an international conference on oncolytic viruses, reflecting his leadership in the field. His lab actively collaborates on projects involving animal modeling, reporter gene imaging, and therapeutic development. His research is affiliated with key centers at Mayo Clinic, including the Mayo Clinic Comprehensive Cancer Center, the Women's Health Research Center, and the Center for Regenerative Biotherapeutics, underscoring the interdisciplinary nature of his work.

• MicroRNA
• Cancer Biology
• Tumor Metabolism
• +۳ مورد دیگر

Francesca ORSO is an Associate Professor at the Department of Translational Medicine , Universita' degli Studi del Piemonte Orientale 'Amedeo Avogadro'. Her research focuses on MicroRNA mechanisms in cancer progression, particularly in Melanoma , Breast Cancer , and Chronic Myeloid Leukemia . She explores how miRNAs regulate Tumor Metabolism , Metastasis , and Drug Resistance , with a strong emphasis on mTORC2 , Angiogenesis , and Tumor Microenvironment interactions. Key Research Areas : MicroRNA, Cancer Biology, Tumor Metabolism, Molecular Biology, Medical Biotechnology, Genetics Recent Trends : Her 2024 publications highlight miR-15a in Leukemia , RICTOR/mTORC2 in Melanoma Resistance , and miR-214 in Lung Cancer Metabolism . Earlier studies (2023-2008) address 3D Culture Systems , AXL-miRNA Sponges , and Transcription Factor Networks in tumor dissemination. Awards : Premio Chiara D'Onofrio Giovani Riercatori (2009)

Yiqiang Zhangمشاهده پروفایل

استادیار

• Cardiovascular Biology
• Stem Cell Biology
• Regenerative Medicine
• +۶ مورد دیگر

Yiqiang Zhang, PhD is an Assistant Professor in the Department of Anatomy, Biochemistry & Physiology at the University of Hawaii John A. Burns School of Medicine, affiliated with the Center for Cardiovascular Research. He holds graduate faculty roles in Developmental and Reproductive Biology (DRB) and Cell and Molecular Biology (CMB). Dr. Zhang earned his B.Sc. in Biology (Zoology) and M.Sc. in Physiology from Sun Yat-sen University (China), followed by a PhD in Biomedical Sciences from the University of Montreal (2006). His postdoctoral training included Johns Hopkins Medicine’s Cardiology Fellowship Program and Cedars-Sinai Medical Center, focusing on developmental cell biology and cardiac electrophysiology. He has held prior roles as a Staff Scientist at City of Hope National Medical Center and Acting Assistant Professor at the University of Washington School of Medicine. His research integrates multi-omics, bioinformatics, and advanced cellular/molecular techniques to study cardiac development, disease mechanisms, and regenerative therapies. Key projects include: epigenetic regulation of cardiomyocyte cell cycle re-entry, single-cell analysis of heart failure mechanisms, and leveraging stem cell models to understand congenital heart defects. His work addresses diabetic cardiomyopathy, arrhythmias, and heart failure through translational approaches. Supported by NIH, American Heart Association, and other funding agencies, his lab seeks to identify novel therapeutic targets for cardiovascular diseases. Dr. Zhang teaches across undergraduate, graduate, and medical programs, emphasizing translational research and clinical education. His contributions span over 60 peer-reviewed publications, including high-impact studies in Cell , Circulation , and Nature journals. Current research emphasizes computational genomics, epigenetic modifiers, and inflammatory pathways in cardiac disorders.

Stefano Menegattiمشاهده پروفایل

دانشیار

• Biomanufacturing
• Peptide-based affinity ligands
• Biopharmaceutical purification
• +۵ مورد دیگر

Stefano Menegatti is an Associate Professor and University Faculty Scholar in the Department of Chemical and Biomolecular Engineering at North Carolina State University (NC State). His research focuses on developing peptide-based technologies for biopharmaceutical purification, drug delivery systems, and advanced biomaterials. He holds a Ph.D. in Chemical Engineering from NC State (2013), and M.Sc. and B.Sc. degrees from the Università di Bologna (Italy). Menegatti’s work emphasizes stimuli-responsive peptide ligands for purifying labile biologics like stem cells and therapeutic proteins, as well as hydrogel systems for controlled drug release. His lab also develops transdermal delivery platforms for vaccines and explores biodegradable polymers for medical devices. He leads the Ligand Design & Biomanufacturing Group within the College of Engineering. Education: Ph.D., Chemical Engineering, NC State (2013) M.Sc., Chemical Engineering, Università di Bologna (2008) B.Sc., Chemical Engineering, Università di Bologna (2006) His research interests span biomanufacturing , viral vector purification , host-cell protein removal , and biodegradable materials . Recent advancements include adaptive machine learning frameworks for viral vector production and shear-responsive nanocoatings for biomedical applications. Awards: ACS BIOT Young Investigator Award (2025) NSF CAREER Award (2017) NCSU Chancellor’s Innovation Fund (2019) Menegatti collaborates with industry partners on process analytical technologies (PAT) and has pioneered peptide ligand systems for AAV, lentivirus, and adenovirus purification. His lab actively explores sustainable biomanufacturing strategies, including engineered microbes for PET plastic degradation.

Chris Boydمشاهده پروفایل

دانشیار

• Gene Therapy
• Cystic Fibrosis Research
• Pulmonary Medicine
• +۵ مورد دیگر

Dr. Chris Boyd is a Reader (equivalent to Associate Professor) at the University of Edinburgh's Institute of Genetics and Cancer, where he leads the Chris Boyd Research Group within the Centre for Genomic and Experimental Medicine. His work focuses on developing pulmonary gene therapy approaches to treat cystic fibrosis and other genetic diseases, with significant contributions to the UK CF Gene Therapy Consortium formed in 2001 by research groups in London, Oxford, and Edinburgh. Dr. Boyd's research program has two main fronts in cystic fibrosis gene therapy. In Wave 1, his team developed and tested a nonviral product (pGM169/GL67A) in a Phase IIb clinical trial that demonstrated the ability to arrest lung function decline. In Wave 2, he is developing a more efficient lentiviral vector (rSIV.F/HN) for delivering transgenes to the lung, with his group assessing safety and monitoring CFTR expression from transduced cells. His expertise spans translational medicine, gene therapy, synthetic biology, recombinant DNA technology, airway cell biology, immunohistochemistry, and genotoxicity. His publication record shows consistent progression from preclinical development through to human trials, with recent work (2022-2024) focusing on lentiviral approaches and biomarker development for monitoring disease progression. This reflects a maturing research program moving toward clinical application. Dr. Boyd collaborates extensively with researchers across the UK, including Dr. Gerry McLachlan and Dr. David Collie at the University of Edinburgh, Prof. Eric Alton and Prof. Jane Davies at Imperial College London, and colleagues at the University of Oxford and University of Bristol. His research is supported by the Cystic Fibrosis Trust, Imperial College of Science Technology and Medicine, Just Gene Therapy, and various charities.

• Gene therapy
• Oncolytic virotherapy
• Immunotherapy
• +۵ مورد دیگر

Professor Noriyuki Kasahara, MD, PhD is a leading faculty member at the University of California, San Francisco (UCSF) within the School of Medicine and Department of Neurological Surgery . He holds a primary appointment as a Professor and is internationally recognized for his pioneering work in gene therapy , oncolytic virotherapy , and immunotherapy , particularly in the context of brain tumors , gliomas , and translational cancer research . Education and Training Dr. Kasahara completed his medical and doctoral training at Tokyo Medical & Dental University , earning his MB in 1986 , MD in 1993 , and PhD in 1994 with a focus on endocrinology . He subsequently pursued residency training in laboratory medicine and postdoctoral fellowship in gene therapy at UCSF and the Howard Hughes Medical Institute . Research Focus His laboratory is dedicated to the development of gene therapy, oncolytic virotherapy, and immunotherapy for translational applications in cancer treatment , with a strong emphasis on glioblastoma , ovarian cancer , pancreatic cancer , and regenerative medicine . A major area of innovation involves the use of retroviral replicating vectors (RRVs) to deliver suicide gene therapy and immune-modulating agents directly to tumors, thereby enhancing antitumor immunity while minimizing systemic toxicity. Key Achievements Dr. Kasahara’s work has led to the development of Toca 511 (vocimagene amiretrorepvec) , a clinically advanced retroviral vector currently in Phase 1 trials for recurrent high-grade glioma . His research has demonstrated durable complete responses in some patients, highlighting the therapeutic potential of prodrug activator gene therapy . Additionally, his group has explored mesenchymal stem cells as cellular carriers for targeted vector delivery, further expanding the applications of gene therapy in oncology. Scientific Awards and Honors Tokyo Medical & Dental University Young Investigators Research Award (1994) UCSF Chancellor Julius R. Krevans’ Distinguished Dissertation Award (1995) Stop Cancer Foundation Career Development Award (1996) Cooley's Anemia Foundation New Investigator Award (1998) UCSF QB3 Clinical Impact Award, Global Life Science Innovation Competition (2006) Grant Support and Funding Dr. Kasahara has served as Principal Investigator on numerous NIH , CIRM , and foundation grants, including: NIH R33NS104454 – GALV-Based Retroviral Replicating Vectors for Glioma Gene Therapy NIH R01CA213119 – Retroviral Replicating Vector-mediated Gene Therapy for Ovarian Cancer CIRM TR2-01791 – Stem cell-based carriers for RCR vector delivery to glioblastoma NIH U01NS059821 – Translational Development of Replication-Competent Retrovirus Vectors Laboratory and Collaborations His research team operates within the UCSF Brain Tumor Center , fostering interdisciplinary collaborations with neuro-oncologists, immunologists, and bioengineers. The lab is focused on next-generation viral vectors , immune reprogramming strategies , and clinical translation of gene therapies for pediatric and adult brain tumors .

• Hematology
• Neutropenia Research
• Pediatric Oncology
• +۵ مورد دیگر

Peter E Newburger is a Professor at UMass Chan Medical School with appointments across multiple departments including Pediatrics, Microbiology, Molecular, Cell and Cancer Biology, and several programs within the Morningside Graduate School of Biomedical Sciences. His primary departmental affiliation is in Pediatrics, specifically within the Division of Pediatrics Hematology/Oncology. Dr. Newburger earned his BA in Chemistry from Haverford College and his MD from Harvard Medical School. His research focuses on hematologic disorders, particularly neutropenia, chronic granulomatous disease, and other blood disorders in children. With over 150 publications spanning from 1983 to 2025, Dr. Newburger's work has significantly advanced understanding of neutropenia pathophysiology, genetic causes, and treatment approaches. His recent research has focused on ELANE mutations in severe congenital neutropenia, gene therapy approaches, and international consensus guidelines for neutropenia management. His work bridges basic molecular research with clinical applications, particularly in pediatric hematology and immunology. Dr. Newburger has been instrumental in establishing the Severe Chronic Neutropenia International Registry and has contributed to numerous clinical guidelines for neutropenia management. His work on chronic granulomatous disease has explored both the molecular basis of the disease and potential therapeutic interventions including interferon gamma and gene therapy approaches. His laboratory investigations have examined the molecular mechanisms of neutrophil development and function, with particular focus on the role of specific genes and proteins in neutropenia pathogenesis. This work has important implications for developing targeted therapies for patients with congenital neutropenia syndromes.

Trey Westbrookمشاهده پروفایل

استاد

• Cancer Genetics
• Breast Cancer Therapeutics
• Oncogene-Induced Stress Pathways
• +۳ مورد دیگر

Trey Westbrook is a Professor at Baylor College of Medicine, holding joint appointments in the Department of Molecular and Human Genetics and the Department of Biochemistry & Molecular Biology. He also serves as Director of the Cell-Based Assay Screening Shared Resource at the Dan L Duncan Comprehensive Cancer Center and holds the McNair Scholar position. His research focuses on cancer genetics, oncogene-induced stress pathways, and translational therapies for aggressive cancers like triple-negative breast cancer (TNBC). Education: B.S. from Allegheny College (1997), Ph.D. from the University of Rochester School of Medicine and Dentistry (2003), and postdoctoral training at Harvard Medical School (2007). Research Interests: Mechanisms of oncogene-induced cellular stresses, functional genetic screens for cancer genes, and drug resistance pathways. Key projects include exploiting stress pathways for therapy development, identifying tumor suppressor networks in TNBC, and dissecting RNA processing stress in cancer. Publications highlight discoveries such as REST tumor suppressor networks, Myc-driven vulnerabilities, and mTOR signaling in immunosuppression. His work bridges basic science with clinical translation, aiming to improve targeted therapies and patient outcomes. Labs/Teams: Leads the Westbrook Lab at Baylor, emphasizing collaborative research in cancer biology, functional genomics, and translational oncology.

Eric Barklisمشاهده پروفایل

استاد

• Virology
• HIV-1 Assembly
• Viral Matrix Proteins
• +۲ مورد دیگر

Eric Barklis is Professor at OHSU's Vollum Institute and directs the Electron Microscope Core Facility. His lab studies retroviral assembly mechanisms and host-pathogen interactions using structural and biochemical approaches. Research examines HIV-1 matrix protein functions, coronavirus entry inhibition, and lipid metabolism in viral replication. Recent work developed neutralizing nanobodies against SARS-CoV-2 variants. Publications characterize viral protein interactions with host membranes and nucleic acids. The lab collaborates extensively on antiviral development and lentiviral vector engineering.

Maria G. Roncaroloمشاهده پروفایل

استاد

• Immunotolerance
• Immunomodulation
• Transplantation
• +۴ مورد دیگر

Maria G. Roncarolo is a distinguished Professor in Pediatrics at the School of Medicine and Surgery, Vita-Salute San Raffaele University in Milan, Italy. She serves as Scientific Director of the San Raffaele Scientific Institute since 2008 and Chief of Clinic for Pediatric Immunology and Hematology and Clinical Research Unit (CRU-P) at San Raffaele Hospital and San Raffaele Scientific Institute since 2003. Her academic career spans prestigious institutions across Europe and the United States, with significant leadership roles in immunology research and clinical practice. Dr. Roncarolo earned her MD from the University of Turin in 1982 with honors, followed by National Board certifications in Pediatrics (1986) and Clinical Immunology (1990), both from the University of Milan. Her educational foundation enabled her transition from research positions in France and at DNAX Research Institute in California to leadership roles in Italian academic medicine. Her research program focuses on the intricate mechanisms of immune regulation, particularly T-cell tolerance and immunomodulation. She investigates how regulatory T cells develop and function in transplantation settings, primary immunodeficiencies, and autoimmune disorders. Her laboratory has pioneered methods for in vitro generation of regulatory T cells and explored gene therapy applications for immunological disorders through hematopoietic stem cell modification. Her work bridges fundamental immunological discoveries with clinical applications for immune-mediated diseases. Analysis of Dr. Roncarolo's publication record shows a consistent research trajectory focused on regulatory T cell biology, particularly Type 1 regulatory (Tr1) cells. Her work spans immunology, gene therapy, and transplantation medicine, with increasing emphasis on translational applications. Key themes include molecular characterization of regulatory T cells, mechanisms of immune suppression, and development of cellular therapies for autoimmune diseases and transplantation tolerance. Dr. Roncarolo's significant contributions have been recognized with prestigious honors: Ufficiale dell'Ordine "Al Merito della Repubblica Italiana" for scientific merits (2000) Election to Member of the Academia Europaea of Sciences (2005) Price "Clessidra d'Oro" from A.D.O. of Italy for transplantation research (1998) Award from "Club degli amici dell'Immunologia" of Italy for clinical immunological research (1986) As Scientific Director of San Raffaele Scientific Institute, Dr. Roncarolo oversees a major research enterprise integrating basic science with clinical research. She serves on numerous international scientific committees including the American Society of Gene and Cell Therapy, European School of Hematology, and International Congress of Immunology. Her leadership has established San Raffaele as a leading European center for translational immunology research. Dr. Roncarolo leads a multidisciplinary research team investigating immune tolerance mechanisms with applications to clinical therapies. Her laboratory maintains strong collaborations with clinical departments to translate discoveries into novel treatments for patients with immune disorders, particularly focusing on cellular therapies to induce immune tolerance in autoimmune diseases and transplantation settings.

Mary Kearns-Jonkerمشاهده پروفایل

دانشیار

• Regenerative Medicine
• Stem Cell Biology
• Xenotransplantation
• +۷ مورد دیگر

Mary Kearns-Jonker is an Associate Professor in the Department of Pathology and Human Anatomy at Loma Linda University School of Medicine and serves as Co-Program Director of the Cancer, Developmental and Regenerative Biology PhD program. Her research is centered on regenerative medicine, with a focus on stem cell biology, xenotransplantation, and the impact of microgravity on cardiovascular progenitor cells. Her research interests span regenerative medicine , stem cell biology , cardiovascular development , and space biomedicine . She investigates how neonatal cardiovascular progenitor cells can be harnessed for cardiac repair, including mechanisms involving YAP1 signaling, extracellular vesicles, and the effects of hypoxia and microgravity. Her lab has pioneered studies on stem cell behavior in space, using the International Space Station to explore how microgravity alters gene expression and functional properties of progenitor cells, with implications for both Earth-based and space-based regenerative therapies. The recent publication trends highlight a strong focus on cardiac regeneration , microgravity effects , biomaterial scaffolds , and transcriptomic analysis . Her work bridges molecular biology, tissue engineering, and translational medicine, with increasing emphasis on space biomanufacturing and biotechnology. Efficient Generation of Integration-Free iPS Cells from Human Adult Peripheral Blood Using BCL-XL Together With Yamanaka Factors (2013) Gene therapy to inhibit xenoantibody production using lentiviral vectors in non-human primates (2007) Dr. Kearns-Jonker has led significant research initiatives, including a project on generating integration-free iPS cells and studies on xenotransplantation immunology. Her work has been supported by research grants related to gene therapy, stem cell transplantation, and spaceflight experiments. She mentors students and researchers in the Cancer, Developmental and Regenerative Biology program and contributes to advancing regenerative therapies for heart failure and organ repair. Her research team actively explores innovative solutions for end-stage organ failure, combining xenotransplantation strategies with stem cell-based repair. Current efforts include biomanufacturing in low Earth orbit and understanding how spaceflight alters stem cell regenerative potential, positioning her at the forefront of space biomedical research.

Stephen E. Braunمشاهده پروفایل

استادیار

• Gene Therapy
• HIV/AIDS Research
• Virology
• +۵ مورد دیگر

Stephen E. Braun is an Assistant Professor of Pharmacology at Tulane University. His research focuses on gene therapy strategies targeting lympho-hematopoietic cells, with a strong emphasis on HIV/AIDS research. He has over 25 years of experience in translational research, including studies in non-human primates (NHP) and clinical trial advancements. His work involves developing CAR T-cell therapies, lentiviral vector engineering, and mesenchymal stem cell-based antiviral approaches. Education: BS in Genetics and Cell Biology, Biochemistry, University of Minnesota (1987) PhD in Genetics, University of Minnesota (1993) Postdoctoral Fellowship at Walther Oncology Center, Indiana University School of Medicine (1993–1997) Research Interests: Dr. Braun’s lab develops novel gene therapy approaches to combat HIV/AIDS, including CAR T-cell redirection, HIV-resistant T-cell engineering, and MSC-mediated viral inhibition. His work bridges in vitro studies with large-animal models and clinical application. Key Awards: NIH Post-Doctoral Training Award (1993–1995) Leukemia Society of America Fellow Award (1995–1998) Center for AIDS Research Scholar Award (2003–2006) Early Investigator Award (30th Annual NHP AIDS Symposium, 2012) Grants & Collaborations: His research has been supported by NIH and private foundations. Collaborations span institutions such as the National Primate Research Centers and the American Society of Gene & Cell Therapy. Labs/Teams: Active in Tulane’s Division of Veterinary Medicine and collaborates with the Comparative Pathology and Immunology research groups.